• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by NuCana plc

    2/14/25 4:32:24 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCNA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)


    NuCana plc

    (Name of Issuer)


    Ordinary Shares, nominal value GBP0.04 per share

    (Title of Class of Securities)


    67022C205

    (CUSIP Number)


    Armance Bordes
    7-11, boulevard Haussmann,
    Paris, I0, 75009
    33 1 76 23 41 09


    John Partigan Lloyd Spencer
    Nixon Peabody LLP, 799 9 Street NW Ste 500
    Washington, DC, 20001
    202-585-8000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    02/14/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Sofinnova Capital VI FCPR
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    FRANCE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    4,987,975.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    4,987,975.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    4,987,975.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.1 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Note in relation to Items 7 and 8: Sofinnova Partners SAS, a French corporation ("SP SAS"), the management company of Sofinnova Capital VI FCPR ("SC VI"), may be deemed to have sole voting power, and Antoine Papiernik ("Papiernik"), Henrijette Richter ("Richter"), Maina Bhaman ("Bhaman"), Graziano Seghezzi ("Seghezzi"), Anta Gkelou ("Gkelou") and Karl Naegler ("Naegler"), the members of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler, the members of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 98,630,000 ordinary shares outstanding as of September 30, 2024, as reported in Exhibit 99.1 in NuCana plc's Form 6-K filed with the SEC on November 25, 2024.


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Sofinnova Partners SAS
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    FRANCE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    4,987,975.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    4,987,975.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    4,987,975.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.1 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Note in relation to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler, the members of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler, the members of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 98,630,000 ordinary shares outstanding as of September 30, 2024, as reported in Exhibit 99.1 in NuCana plc's Form 6-K filed with the SEC on November 25, 2024.


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Antoine Papiernik
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    FRANCE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    4,987,975.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    4,987,975.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    4,987,975.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.1 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 98,630,000 ordinary shares outstanding as of September 30, 2024, as reported in Exhibit 99.1 in NuCana plc's Form 6-K filed with the SEC on November 25, 2024.


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Henrijette Richter
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DENMARK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    4,987,975.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    4,987,975.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    4,987,975.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.1 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Richter, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Richter, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 98,630,000 ordinary shares outstanding as of September 30, 2024, as reported in Exhibit 99.1 in NuCana plc's Form 6-K filed with the SEC on November 25, 2024.


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Maina Bhaman
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    4,987,975.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    4,987,975.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    4,987,975.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.1 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Bhaman, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Bhaman, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 98,630,000 ordinary shares outstanding as of September 30, 2024, as reported in Exhibit 99.1 in NuCana plc's Form 6-K filed with the SEC on November 25, 2024.


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Graziano Seghezzi
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    ITALY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    4,987,975.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    4,987,975.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    4,987,975.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.1 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Seghezzi, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Seghezzi, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 98,630,000 ordinary shares outstanding as of September 30, 2024, as reported in Exhibit 99.1 in NuCana plc's Form 6-K filed with the SEC on November 25, 2024.


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Anta Gkelou
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    GREECE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    4,987,975.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    4,987,975.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    4,987,975.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.1 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Gkelou, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Gkelou, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 98,630,000 ordinary shares outstanding as of September 30, 2024, as reported in Exhibit 99.1 in NuCana plc's Form 6-K filed with the SEC on November 25, 2024.


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Karl Naegler
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    GERMANY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    4,987,975.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    4,987,975.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    4,987,975.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.1 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Naegler, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Naegler, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 98,630,000 ordinary shares outstanding as of September 30, 2024, as reported in Exhibit 99.1 in NuCana plc's Form 6-K filed with the SEC on November 25, 2024.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares, nominal value GBP0.04 per share
    (b)Name of Issuer:

    NuCana plc
    (c)Address of Issuer's Principal Executive Offices:

    3 Lochside Way, Edinburgh, UNITED KINGDOM , EH12 9DT.
    Item 1 Comment:
    Introductory Statement: This Amendment No. 6 ("Amendment No. 6"), being filed by Sofinnova Capital VI FCPR ("SC VI"), Sofinnova Partners SAS, a French corporation ("SP SAS"), Antoine Papiernik ("Papiernik"), Henrijette Richter ("Richter"), Maina Bhaman ("Bhaman"), Graziano Seghezzi ("Seghezzi"), Anta Gkelou ("Gkelou") and Karl Naegler ("Naegler"), the investment committee of SC VI (collectively, the "Listed Persons" and together with SC VI and SP SAS, the "Reporting Persons"), amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on February 21, 2018, as amended by Amendment No. 1 to Schedule 13D filed with the SEC on February 14, 2019, as further amended by Amendment No. 2 to Schedule 13D filed with the SEC on February 12, 2020, as further amended by Amendment No. 3 to Schedule 13D filed with the SEC on October 28, 2020, as further amended by Amendment No. 4 to Schedule 13D filed with the SEC on February 2, 2021, and as further amended by Amendment No. 5 to Schedule 13D filed with the SEC on June 15, 2021 (collectively, the "Schedule 13D"). This Schedule 13D relates to the ordinary shares (the "Ordinary Shares") of NuCana plc, an English corporation (the "Issuer"), as represented by American Depositary Shares ("ADSs"). Except as specifically provided herein, this Amendment No. 6 does not modify any of the information previously reported in the Schedule 13D, as amended. Capitalized terms used herein shall have the meanings ascribed to them in the Schedule 13D.
    Item 2.Identity and Background
    (d)
    None of the Reporting Persons has during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors).
    (e)
    None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.
    Item 4.Purpose of Transaction
     
    Item 4 of the Schedule 13D is hereby amended and supplemented as follows: All of the Ordinary Shares and ADSs that are held of record by the Reporting Persons as reported herein were acquired for investment purposes. The Reporting Persons retain the right to change their investment intent, from time to time to acquire additional ADSs or other securities of the Issuer, or to sell or otherwise dispose of all or part of the ADSs or other securities of the Issuer, if any, beneficially owned by them, in any manner permitted by law. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein. Except as set forth above, none of the Reporting Persons currently has any plans or proposals which would be related to or would result in any of the matters described in Items 4(a)-(j) of the Instructions to Schedule 13D. However, as part of the ongoing evaluation of investment and investment alternatives, the Reporting Persons may consider such matters and, subject to applicable law, may formulate a plan with respect to such matters, and, from time to time, may hold discussions with or make formal proposals to management or the board of directors of the Issuer or other third parties regarding such matters.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: See Rows 11 and 13 of the cover page for each of the Filing Persons, which is incorporated herein by reference. The filing of this Schedule 13D shall not be construed as an admission by Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler that such person is, for the purposes of Section 13(d) of the Securities Exchange Act of 1934, the beneficial owner of any securities covered by this Statement. This Amendment is being filed to reflect a decrease in the Reporting Persons' percentage ownership of the Issuer's Ordinary Shares, which resulted from an increase in the number of Ordinary Shares outstanding since the filing of Amendment No. 5 to Schedule 13D and is not due to any transactions in the Ordinary Shares or ADSs by the Reporting Persons. Percentage of class is calculated based on 98,630,000 ordinary shares outstanding as of September 30, 2024, as reported in Exhibit 99.1 in NuCana plc's Form 6-K filed with the SEC on November 25, 2024.
    (b)
    Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: See the information contained on the cover pages of this Amendment, which is incorporated herein by reference.
    (c)
    Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: There have been no reportable transactions with respect to the Ordinary Shares or ADSs of the Issuer within the last 60 days by the Reporting Persons.
    Item 7.Material to be Filed as Exhibits.
     
    EX 99.1 - Joint Filing Agreement, dated as of February 14, 2025.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Sofinnova Capital VI FCPR
     
    Signature:/s/ Antoine Papiernik
    Name/Title:Antoine Papiernik / Managing Partner
    Date:02/14/2025
     
    Sofinnova Partners SAS
     
    Signature:/s/ Antoine Papiernik
    Name/Title:Antoine Papiernik / Managing Partner
    Date:02/14/2025
     
    Antoine Papiernik
     
    Signature:/s/ Antoine Papiernik
    Name/Title:Antoine Papiernik
    Date:02/14/2025
     
    Henrijette Richter
     
    Signature:/s/ Henrijette Richter
    Name/Title:Henrijette Richter
    Date:02/14/2025
     
    Maina Bhaman
     
    Signature:/s/ Maina Bhaman
    Name/Title:Maina Bhaman
    Date:02/14/2025
     
    Graziano Seghezzi
     
    Signature:/s/ Graziano Seghezzi
    Name/Title:Graziano Seghezzi
    Date:02/14/2025
     
    Anta Gkelou
     
    Signature:/s/ Anta Gkelou
    Name/Title:Anta Gkelou
    Date:02/14/2025
     
    Karl Naegler
     
    Signature:/s/ Karl Naegler
    Name/Title:Karl Naegler
    Date:02/14/2025
    Get the next $NCNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NCNA

    DatePrice TargetRatingAnalyst
    8/30/2024Outperform → Mkt Perform
    William Blair
    3/3/2022Outperform → Market Perform
    Cowen & Co.
    11/24/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NCNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NuCana downgraded by William Blair

    William Blair downgraded NuCana from Outperform to Mkt Perform

    8/30/24 7:44:58 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana downgraded by Cowen & Co.

    Cowen & Co. downgraded NuCana from Outperform to Market Perform

    3/3/22 6:12:40 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on NuCana with a new price target

    HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously

    11/24/21 6:13:12 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

    Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued Listing Criteria Well Capitalized with Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced financial results for the third quarter ended September 30, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. "We recently announced promising data for both NUC-7738 and NUC-3373 that continue to support the potential of our ProTides to deliver

    11/13/25 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

    EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced that the China National Intellectual Property Administration ("CNIPA") has granted an important patent covering the composition of matter for NUC-7738.   This patent (ZL 202010794701.2) is expected to serve as a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition of matter patent covers the chemical structure of NUC-7738, NuCana's novel anti-cancer agent currently being evaluated in a Phase 1/2 clinical study (NuTide:701) in combination with pembrolizumab for patients with PD-1 inhibitor re

    11/5/25 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    SEC Filings

    View All

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    1/6/26 8:11:52 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    12/17/25 8:12:19 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    12/10/25 8:15:43 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Leadership Updates

    Live Leadership Updates

    View All

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

    EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized

    11/1/21 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

    EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and

    8/10/21 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NuCana plc

    SC 13G/A - NuCana plc (0001709626) (Subject)

    10/4/24 10:14:46 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by NuCana plc (Amendment)

    SC 13D/A - NuCana plc (0001709626) (Subject)

    2/27/24 4:29:36 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NuCana plc (Amendment)

    SC 13G/A - NuCana plc (0001709626) (Subject)

    2/14/24 4:26:01 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care